{
    "root": "b0f65c2b-ee14-421f-9f24-178e108e38cf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "AMPYRA",
    "value": "20250505",
    "ingredients": [
        {
            "name": "DALFAMPRIDINE",
            "code": "BH3B64OKL9",
            "drugbank_id": "https://go.drugbank.com/drugs/DB06637"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        }
    ],
    "indications": {
        "text": "ampyra indicated treatment improve walking adult patients multiple sclerosis ( multiple sclerosis ) . demonstrated increase walking speed [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "multiple sclerosis (DOID:2377)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2377"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "maximum recommended 10 mg twice daily ( approximately 12 hours apart ) . evidence additional benefit doses greater 10 mg twice daily . , including seizures , frequent higher doses . ( 2.1 ) take without food . administer tablets whole ; divide , crush , chew , dissolve ( 2.2 ) patients take double extra doses miss dose . ( 2.2 ) estimated creatinine clearance ( crcl ) known initiating treatment ampyra . patients mild renal impairment ( crcl 51\u201380 ml/min ) , ampyra may reach plasma levels associated greater risk seizures , potential benefits ampyra carefully considered risk seizures patients ( 2.3 , 5.2 , 8.6 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ampyra ( dalfampridine ) extended release tablets , 10 mg film-coated , white off-white , biconvex , oval shaped , non-scored tablets flat edge . tablets identified debossed code `` a10 `` one side available bottles 60. ndc 0259-5010-60 bottles 60 tablets",
    "adverseReactions": "ampyra contraindicated following conditions : history seizure [ ( 5.1 ) ] moderate severe renal impairment ( crcl\u226450 ml/min ) [ ( 5.2 ) ] history hypersensitivity ampyra 4-aminopyridine ; included anaphylaxis [ ( 5.4 ) ]",
    "indications_original": "AMPYRA is indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14)].",
    "contraindications_original": "The maximum recommended dosage is 10 mg twice daily (approximately 12 hours apart). There is no evidence of additional benefit with doses greater than 10 mg twice daily. Adverse reactions, including seizures, were more frequent at higher doses. ( 2.1 ) Take with or without food. Administer tablets whole; do not divide, crush, chew, or dissolve ( 2.2 ) Patients should not take double or extra doses if they miss a dose. ( 2.2 ) Estimated creatinine clearance (CrCl) should be known before initiating treatment with AMPYRA. In patients with mild renal impairment (CrCl 51\u201380 mL/min), AMPYRA may reach plasma levels associated with a greater risk of seizures, and the potential benefits of AMPYRA should be carefully considered against the risk of seizures in these patients ( 2.3 , 5.2 , 8.6 )",
    "warningsAndPrecautions_original": "AMPYRA (dalfampridine) extended release tablets, 10 mg are film-coated, white to off-white, biconvex, oval shaped, non-scored tablets with flat edge. The tablets are identified by a debossed code \"A10\" on one side and are available in bottles of 60.\n                  \n                     NDC 0259-5010-60 bottles of 60 tablets",
    "adverseReactions_original": "The use of AMPYRA is contraindicated in the following conditions:\n                  \n                     History of seizure [see Warnings and Precautions (5.1)]\n                     \n                     Moderate or severe renal impairment (CrCl\u226450 mL/min) [see \n                           Warnings and Precautions (5.2)\n                        ]\n                     History of hypersensitivity to AMPYRA or 4-aminopyridine; reactions have included anaphylaxis [see \n                           Warnings and Precautions (5.4)\n                        ]",
    "drug": [
        {
            "name": "AMPYRA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB06637"
        }
    ]
}